¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"angle methyl group"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • angle-closure glaucoma
    Æó¼â°¢³ì³»Àå
  • angle-rotation flap
    °¢µ¹¸²ÇÇÆÇ
  • anterior chamber angle
    ¾Õ¹æ°¢, Àü¹æ°¢
  • closed angle glaucoma
    Æó¼â°¢³ì³»Àå
  • columellolabial angle
    ÄÚ±âµÕÀÔ¼ú°¢
  • conchoscaphal angle
    ¼±¹Ý¹è°¢
  • costal angle
    °¥ºñ»À°¢, ´Á°ñ°¢
  • costophrenic angle
    °¥ºñ°¡·Î¸·°¢, ´Á°ñȾ°Ý¸·°¢
  • costovertebral angle
    °¥ºñôÃß°¢, ´Á°ñôÃß°¢
  • craniofacial angle
    ¸Ó¸®¾ó±¼°¢, µÎ°³¾È¸é°¢
  • cardiodiaphragmatic angle
    ½ÉÀå°¡·Î¸·°¢, ½ÉÀåȾ°Ý¸·°¢
  • cardiophrenic angle
    ½ÉÀå°¡·Î¸·°¢, ½ÉÀåȾ°Ý¸·°¢
  • cerebellopontine angle
    ¼Ò³ú´Ù¸®³ú°¢
  • cerebellopontine angle meningioma
    ¼Ò³ú´Ù¸®³ú°¢¼ö¸·Á¾, ¼Ò³ú±³³ú°¢¼ö¸·Á¾
  • cervicomental angle
    ¸ñÅγ¡°¢
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • minority group
    ¼Ò¼öÁý´Ü
  • nonionic polar group
    ºñÀ̿±ؼº±â
  • open group
    °ø°³Áý´Ü, °³¹æÁý´Ü
  • osmophore group
    ¹ßÇâ´Ü
  • prosthetic group
    ¹èÇÕ±º
  • self-help group
    ÀÚÁ¶Áý´Ü
  • soluble group
    °¡¿ëÇØ±º
  • symmetry group
    ´ëαº
  • taxonomic group
    ºÐ·ùÁý´Ü
  • topological group
    À§»ó±º
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªºÐ¼®(¹ý)
  • Rh blood group system
    ¾Ë¿¡ÃëÇ÷¾×Çü±º
  • angle
    °¢, ±¸¼®
  • angle correction
    °¢±³Á¤
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • precession angle
    ¼¼Â÷ °¢
  • primary angle-closure glaucoma
    ¿ø¹ßÆó¼â°¢³ì³»Àå
  • primary open-angle glaucoma
    ¿ø¹ß°³¹æ°¢³ì³»Àå
  • pubic angle ³ª angulus pubis
    Ä¡°ñ°¢ (ö»ÍéÊÇ).
  • renal angle
    ½Å°¢.
  • ABO blood group
    ABO Ç÷¾×Çü.
  • ABO blood group system
    ABOÇ÷¾×Çü°è(Åë).
  • ABO blood group=ABO system
    ABO Ç÷¾×Çü
  • Coxsackie group A
    ÄÛ»èŰ A±º.
  • Coxsackie group B
    ÄÛ»èŰ B±º.
  • Diego blood group system
    µð¿¡°í Ç÷¾×Çü°è
  • GCR= group conformity rating
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù.
  • Gag => group specifiic antigen/core
    ±×·ì<±º>ƯÀ̼º Ç׿ø/ÄÚ¾î
  • Kell blood group system
    ÄÌÇ÷¾×Çü±º
  • Kidd blood group system
    ۵åÇ÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • directive group therapy
    Áö½Ã¼º Áý´Ü¿ä¹ý
  • discrepancy in ABO blood group
    ABO Ç÷¾×ÇüºÒÀÏÄ¡
  • end group
    ¸»´Ü±â.
  • enteric group
    Àå°è¼¼±Õ±º, Àå³»¼¼±Õ±º
  • evocative group therapy
    Ç¥ÇöÀû Áý´Ü¿ä¹ý(øúúÞîÜó¢Ó¥ÖûÛö)
  • frontal group of aphasia
    ÀüµÎ¿±½Ç¾î±º(¡­ã÷åÞÏØ).
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ).
  • glucophore group
    ´ã´ç±â.
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • group
    ±º
  • group I fiber
    Á¦¥°±º¼¶À¯(ð¯ìéÏØàéë«).
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
  • glycoaldehyde group
    ±Û¶óÀÌÄھ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycolaldehyde group
    ±Û¶óÀÌÄݾ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycoloyl group
    ±Û¶óÀÌÄÚ·ÎÀϱâ(Ðñ)
  • glycolyl group
    ±Û¶óÀÌÄÚ¸±±â(Ðñ)
  • glycosyl group
    ±Û¶óÀÌÄڽDZâ(Ðñ)
  • Gm group
    Gm ±â(Ðñ)
  • group specificity
    ±â(Ðñ) ƯÀ̼º(÷åì¶àõ)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • group transfer potential
    ¿øÀÚ´Ü ÀüÀÌ ÀüÀ§(ê«í­Ó¥ï®ì¹Úãëë)
  • group translocation
    ¹«¸® ÀüÀ§(ï®êÈ)
  • guanidinium group
    ±¸¾Æ´Ïµð´Ï¿ò±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CVA   1) Cardio-Vascular Accident(Attack)
  2) Cerebro-Vascular Accident(Attack);...
FLASH Fast Low Angle SHot
PUV Posterior Urethro-Vesical angle
AACG acute angle closure glaucoma
AGE acrylamide gel; acute gastroenteritis; advanced glycation end product; agarose gel electrophoresis; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CP-MAS Cross Polarisation Magic Angle Spinning
FLASH Fast Low Angle SHot
FALS Forward-angle light scatter
hr-MAS High-resolution magic angle spinning
LogMAR Logarithm of the minimum angle of resolution
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Angle's classification of malocclusion Class II
    ºÎÁ¤±³ÇÕÀÇ Angle ºÐ·ù 2±Þ
    ÇÏ¾Ç Á¦ 1´ë±¸Ä¡°¡ »ó¾Ç Á¦ 1´ë±¸Ä¡¿ÍÀÇ °ü°è¿¡¼­ ¿ø½É ȤÀº ÈĹ濡 À§Ä¡ÇÏ´Â ºÎÁ¤±³ÇÕ.
  • Angle's classification of malocclusion division 1
    ºÎÁ¤±³ÇÕÀÇ Angle ºÐ·ù 1·ù
    »óÇÏ¾Ç Á¦ 1´ë±¸Ä¡°¡ ¿ø½É±³ÇÕÀÇ ¾ç»óÀ» º¸À̸鼭 »ó¾Ç ÀüÄ¡ÀÇ °úµµÇÑ ¼øÃø °æ»ç°¡ Ư¡ÀÎ ºÎÁ¤±³ÇÕ.
  • Angle's classification of occlusion
    ±³ÇÕÀÇ Angle ºÐ·ù, ¾Þ±Û¾¾ ºÐ·ù
    1. »óÇÏ¾Ç ±¸Ä¡¿Í ÀýÄ¡ °ü°è¿¡ ±Ù°ÅÇÑ ±³ÇÕÀÇ ºÐ·ù. 2. óÀ½¿¡ ¾Þ±Û¿¡ ÀÇÇØ ±â¼úµÈ ÀüÈÄ¹æ ¾Ç°£ °ü°è¿¡ ´ëÇØ 4°¡Áö ÁÖ¿ä ±¸ºÐÀ¸·Î ¼³¸íµÇ¾ú´ø Á¦ 1´ë±¸Ä¡ÀÇ ±³ÇÕ ¾ç»ó¿¡ ±âÃʸ¦ µÐ ±³Çպзù¹ý.
  • angle`s splint
    ¾Þ±Û ºÎ¸ñ
    ÇÏ¾Ç °ñÀý¿¡ ´ëÇÑ ºÎ¸ñ.
  • anterior chamber angle recession
    Àü¹æ°¢ ÈÄÅð
  • basal angle
    µÎÀú °¢
  • Bennet angle
    Ãø¹æ °ú·Î °æ»ç°¢
    ºñÀÛ¾÷Ãø °úµÎ °æ»ç·Î Áï mandibular lateral translation°ú ½Ã»ó¸é »çÀÌ¿¡ ¼öÆò¸é¿¡¼­ Çü¼ºµÈ °¢µµ.
  • bisecting angle technique
    µî°¢ ÃÔ¿µ¹ý, À̵îºÐ°¢ ÃÔ¿µ¹ý
  • Brewster's angle
    Brewster °¢
  • Camper's angle
    įÆÛ °¢
    ÅÎÀÌ µ¹Ãâ, ÈÄÅðÇÑ Á¤µµ¸¦ ³ªÅ¸³»´Â °ÍÀ¸·Î ºñ±Ù Á¡°ú
  • carrying angle
    ¿î¹Ý °¢µµ
  • cerebellopontine angle
    ¼Ò³ú±³ °¢ºÎ
  • chamfer angle
    èÆÛ °¢
  • chronic closed angle glaucoma
    ¸¸¼º Æó¼â°¢ ³ì³»Àå
  • colic angle
    °áÀå°¢
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
pyribenzyl methyl sulfate 2-(hydroxymethyl)-1,1-dimethylpiperidinium methyl sulfate benzylate;an anticholinergic agent.
Synonym: pyribenzyl methyl sulfate.
(05 Mar 2000)
NADH-methyl viologen reductase <enzyme> Fad-protein from rhodospirillum rubrum which also reduces methylene blue and 2,6-dichlorophenol-indophenol
Registry number: EC 1.6.-
(26 Jun 1999)
ng-nitroarginine methyl ester <chemical> A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.
Pharmacological action: enzyme inhibitors.
(12 Dec 1998)
n-methyl-3,4-methylenedioxyamphetamine <chemical> An n-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as mdma or ecstasy.
Pharmacological action: adrenergic uptake inhibitors, hallucinogens, serotonin agents.
Chemical name: 1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-
(12 Dec 1998)
N methyl D aspartate receptor <physiology> Glutamate receptor sub type (see excitatory amino acids). N methyl D aspartate receptor channels seem to be potentiated by intracellular arachidonic acid.
Acronym: NMDA
(26 Mar 1998)
N-methyl, D-aspartic acid n methyl D aspartate receptor
isoprenylcysteine methyl ester hydrolase <enzyme> Acts on proteins post-translationally isoprenylated on a cysteine 3 amino acids in from the carboxy terminus, followed by carboxymethylation
Registry number: EC 3.1.1.-
Synonym: isoprenylcys methylase
(26 Jun 1999)
tosylarginine methyl ester <chemical> N(2)-(p-tolylsulfonyl)-l-arginine, methyl ester. Arginine derivative which is a substrate for many proteolytic enzymes. As a substrate for the esterase from the first component of complement, it inhibits the action of c(l) on c(4).
Chemical name: L-Arginine, N2-((4-methylphenyl)sulfonyl)-, methyl ester
(12 Dec 1998)
tosylarginine methyl ester hydrolase <enzyme> Protease from sea urchin (arbacia punctulata) eggs; fertilization in the sea urchin is accompanied by the release of this protease from eggs into the surrounding seawater; enzyme uses tame as substrate; used as a measure of trypsin-like activity; tryptase (formerly here) is mast cell tryptase (EC 3.4.21.59)
Registry number: EC 3.4.-
Synonym: tame hydrolase, tame esterase, esterase a2, n-tosyl-l-arginine methyl ester esterase, tamase, tamase-1
(26 Jun 1999)
1-methyl-3-isobutylxanthine <chemical> 3,7-dihydro-1-methyl-3-(2-methylpropyl)-1h-purine-2,6-dione. A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates cyclic nucleotide-dependent protein kinases.
Pharmacological action: phosphodiesterase inhibitors.
Chemical name: 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-
(12 Dec 1998)
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine <chemical> 1,2,3,6-tetrahydro-1-methyl-4-phenylpyridine. A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in parkinson disease. These toxic effects can be prevented by the administration of selective monoamine oxidase inhibitors. Since the cellular toxicity of the compound is similar to that observed in idiopathic parkinson disease, experimental studies with this compound can suggest new opportunities for effective therapy. The compound also induces duodenal ulcers.
Pharmacological action: dopamine agents.
Chemical name: Pyridine, 1,2,3,6-tetrahydro-1-methyl-4-phenyl-
(12 Dec 1998)
1-methyl-4-phenylpyridinium <chemical> 1-methyl-4-phenylpyridinium (mpp+). An active neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp). The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to paraquat, has also been used as an herbicide.
Pharmacological action: dopamine agents, herbicides.
Chemical name: Pyridinium, 1-methyl-4-phenyl-
(12 Dec 1998)
2-methyl branched-chain enoyl-CoA reductase <enzyme> Important in the reversal of beta-oxidation under anaerobic conditions in ascaris suum
Registry number: EC 1.3.1.52
Synonym: 2-methyl bce-CoA reductase
(26 Jun 1999)
3-(2,4--dioxo-6-methyl-5-pyrimidinyl)acrylic acid synthase <enzyme> Involved in sparsomycin biosynthesis; catalyses conversion of 3-(4-oxo-6-methyl-5-pyrimidinyl)acrylic acid to 3-(2,4-dioxo-6-methyl-5-pyrimidinyl)acrylic acid
Registry number: EC 1.14.13.-
Synonym: (e)-uca synthase
(26 Jun 1999)
(3-(5-methyl-2-thienyl)acryloyl)chymotrypsin Pharmacological action: indicator and reagent
Synonym: 3-mtac
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • group
    ¹«¸®;ºñÇà ´ë´ë;ºñÇà ¿¬´ë
  • group
    ¸ðÀ¸(ÀÌ)´Ù;ºÐ·ùÇÏ´Ù
  • group captain
    °ø±º ´ë·É
  • group dynamics
    Áý´Ü ¿ªÇÐ
  • group grope
    È¥À½ ÆÄƼ;Áý´Ü Á¢ÃË
  • group insurance
    ´Üü º¸Çè
  • group marriage
    (¹Ì°³ ÀÎÁ¾ÀÇ) Áý´Ü °áÈ¥;ÀâÈ¥
  • group medicine
    =GROUP PRACTICE
  • group mind
    ±ºÁß ½É¸®
  • group practice
    (¿©·¯ Àü¹®ÀÇÀÇ)Áý´Ü ÀÇ·á;(¿©·¯ ȯÀÚ¿¡ ´ëÇÑ)Áý´Ü °ËÁø ,
  • group psychology
    ±ºÁß ½É¸®ÇÐ
  • group sex
    Áý´Ü ¼º±³
  • group theory
    ±º·Ð
  • group therapy
    Áý´Ü ¿ä¹ý
  • group velocity
    (ÆÄµ¿ÀÇ)±º¼Óµµ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á